FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009369472> ?p ?o ?g. }

• W2009369472 endingPage "11871" @default.
• W2009369472 startingPage "11866" @default.
• W2009369472 abstract "Recombinant α1-antitrypsin with a P1 arginine residue (Arg-α1-antitrypsin) is a rapid inhibitor of both thrombin and activated protein C (APC). A series of mutants were made in an attempt to increase the specificity of this serpin for thrombin over APC. Initially, P2 and P’1 residues of Arg-α1-antitrypsin were replaced in single and double mutations by the corresponding residues in antithrombin and C1 inhibitor which are very poor inhibitors of APC. No improvement in selectivity was achieved by these mutations. In fact, all P2/P’1 substitutions led to a decrease in selectivity for thrombin over APC. For example, replacement of the P2 proline of Arg-α1-antitrypsin by glycine decreased the association rate constant (kass) with thrombin by 37-fold while the kass value with APC was reduced by only 16-fold. Co-operative effects were observed with the double P2 and P’1 substitutions; the mutational effects were not additive. The decrease in the kass for thrombin caused by the mutation of the P2 proline to alanine or glycine was 3-fold greater when threonine was present in the P’1 position instead of the normal serine. In contrast to the disappointing results with the P2/P’1 mutations, replacement of the P7 to P’3 residues of α1-antitrypsin by those of antithrombin led to a dramatic increase in selectivity. Although this substitution only affected the kass value with thrombin by 10-fold, a 12,500-fold decrease in this value with APC was observed. Substitution of proline for the P2 glycine of this chimeric serpin increased the kass values with thrombin and APC by 7- and 90-fold, respectively. The effect of the P2 substitution was again found to depend on the sequence surrounding the residue; the change in the kass for APC caused by the P2 Pro → Gly replacement was 6-fold larger in the chimeric serpin. Evaluation of the kass values of the chimeric serpin with a P2 proline in light of the likely rates of inhibition of thrombin and APC during antithrombotic therapy with heparin suggested that this serpin may have kinetic parameters suitable for an antithrombotic agent. Recombinant α1-antitrypsin with a P1 arginine residue (Arg-α1-antitrypsin) is a rapid inhibitor of both thrombin and activated protein C (APC). A series of mutants were made in an attempt to increase the specificity of this serpin for thrombin over APC. Initially, P2 and P’1 residues of Arg-α1-antitrypsin were replaced in single and double mutations by the corresponding residues in antithrombin and C1 inhibitor which are very poor inhibitors of APC. No improvement in selectivity was achieved by these mutations. In fact, all P2/P’1 substitutions led to a decrease in selectivity for thrombin over APC. For example, replacement of the P2 proline of Arg-α1-antitrypsin by glycine decreased the association rate constant (kass) with thrombin by 37-fold while the kass value with APC was reduced by only 16-fold. Co-operative effects were observed with the double P2 and P’1 substitutions; the mutational effects were not additive. The decrease in the kass for thrombin caused by the mutation of the P2 proline to alanine or glycine was 3-fold greater when threonine was present in the P’1 position instead of the normal serine. In contrast to the disappointing results with the P2/P’1 mutations, replacement of the P7 to P’3 residues of α1-antitrypsin by those of antithrombin led to a dramatic increase in selectivity. Although this substitution only affected the kass value with thrombin by 10-fold, a 12,500-fold decrease in this value with APC was observed. Substitution of proline for the P2 glycine of this chimeric serpin increased the kass values with thrombin and APC by 7- and 90-fold, respectively. The effect of the P2 substitution was again found to depend on the sequence surrounding the residue; the change in the kass for APC caused by the P2 Pro → Gly replacement was 6-fold larger in the chimeric serpin. Evaluation of the kass values of the chimeric serpin with a P2 proline in light of the likely rates of inhibition of thrombin and APC during antithrombotic therapy with heparin suggested that this serpin may have kinetic parameters suitable for an antithrombotic agent." @default.
• W2009369472 created "2016-06-24" @default.
• W2009369472 creator A5005679926 @default.
• W2009369472 creator A5045465592 @default.
• W2009369472 creator A5052072964 @default.
• W2009369472 creator A5067125160 @default.
• W2009369472 date "1995-05-01" @default.
• W2009369472 modified "2023-10-16" @default.
• W2009369472 title "Development of a Novel Recombinant Serpin with Potential Antithrombotic Properties" @default.
• W2009369472 cites W1488537590 @default.
• W2009369472 cites W1518197977 @default.
• W2009369472 cites W1539813719 @default.
• W2009369472 cites W1559723325 @default.
• W2009369472 cites W1563535758 @default.
• W2009369472 cites W1565052686 @default.
• W2009369472 cites W1578821085 @default.
• W2009369472 cites W1593430977 @default.
• W2009369472 cites W1595445711 @default.
• W2009369472 cites W1634475175 @default.
• W2009369472 cites W174314576 @default.
• W2009369472 cites W1769345735 @default.
• W2009369472 cites W1964399899 @default.
• W2009369472 cites W1964452942 @default.
• W2009369472 cites W1983190072 @default.
• W2009369472 cites W1983659508 @default.
• W2009369472 cites W1985407614 @default.
• W2009369472 cites W1989493467 @default.
• W2009369472 cites W1991310060 @default.
• W2009369472 cites W2013547341 @default.
• W2009369472 cites W2017756393 @default.
• W2009369472 cites W2023682043 @default.
• W2009369472 cites W2046574852 @default.
• W2009369472 cites W2049576685 @default.
• W2009369472 cites W2080416943 @default.
• W2009369472 cites W2085873519 @default.
• W2009369472 cites W2086150454 @default.
• W2009369472 cites W2112348962 @default.
• W2009369472 cites W2118723909 @default.
• W2009369472 cites W2121897924 @default.
• W2009369472 cites W2152554526 @default.
• W2009369472 cites W2212388653 @default.
• W2009369472 cites W2270063463 @default.
• W2009369472 cites W2276861322 @default.
• W2009369472 cites W2313611352 @default.
• W2009369472 cites W2313878429 @default.
• W2009369472 cites W2328805967 @default.
• W2009369472 cites W4248750125 @default.
• W2009369472 doi "https://doi.org/10.1074/jbc.270.20.11866" @default.
• W2009369472 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7744836" @default.
• W2009369472 hasPublicationYear "1995" @default.
• W2009369472 type Work @default.
• W2009369472 sameAs 2009369472 @default.
• W2009369472 citedByCount "43" @default.
• W2009369472 countsByYear W20093694722012 @default.
• W2009369472 countsByYear W20093694722013 @default.
• W2009369472 countsByYear W20093694722014 @default.
• W2009369472 countsByYear W20093694722017 @default.
• W2009369472 countsByYear W20093694722018 @default.
• W2009369472 countsByYear W20093694722019 @default.
• W2009369472 countsByYear W20093694722021 @default.
• W2009369472 countsByYear W20093694722022 @default.
• W2009369472 crossrefType "journal-article" @default.
• W2009369472 hasAuthorship W2009369472A5005679926 @default.
• W2009369472 hasAuthorship W2009369472A5045465592 @default.
• W2009369472 hasAuthorship W2009369472A5052072964 @default.
• W2009369472 hasAuthorship W2009369472A5067125160 @default.
• W2009369472 hasBestOaLocation W20093694721 @default.
• W2009369472 hasConcept C104317684 @default.
• W2009369472 hasConcept C126322002 @default.
• W2009369472 hasConcept C143065580 @default.
• W2009369472 hasConcept C153911025 @default.
• W2009369472 hasConcept C181199279 @default.
• W2009369472 hasConcept C185592680 @default.
• W2009369472 hasConcept C2775880066 @default.
• W2009369472 hasConcept C2776414213 @default.
• W2009369472 hasConcept C2777292125 @default.
• W2009369472 hasConcept C2777557582 @default.
• W2009369472 hasConcept C2778965386 @default.
• W2009369472 hasConcept C2779026020 @default.
• W2009369472 hasConcept C2779815552 @default.
• W2009369472 hasConcept C2779856020 @default.
• W2009369472 hasConcept C2781287897 @default.
• W2009369472 hasConcept C2910323407 @default.
• W2009369472 hasConcept C515207424 @default.
• W2009369472 hasConcept C55493867 @default.
• W2009369472 hasConcept C71924100 @default.
• W2009369472 hasConcept C86803240 @default.
• W2009369472 hasConcept C89560881 @default.
• W2009369472 hasConceptScore W2009369472C104317684 @default.
• W2009369472 hasConceptScore W2009369472C126322002 @default.
• W2009369472 hasConceptScore W2009369472C143065580 @default.
• W2009369472 hasConceptScore W2009369472C153911025 @default.
• W2009369472 hasConceptScore W2009369472C181199279 @default.
• W2009369472 hasConceptScore W2009369472C185592680 @default.
• W2009369472 hasConceptScore W2009369472C2775880066 @default.
• W2009369472 hasConceptScore W2009369472C2776414213 @default.
• W2009369472 hasConceptScore W2009369472C2777292125 @default.
• W2009369472 hasConceptScore W2009369472C2777557582 @default.

• next